

Role of miRâ€223â€ in pulmonary arterial hypertension ECM pathway

Cell Proliferation

52, e12550

DOI: [10.1111/cpr.12550](https://doi.org/10.1111/cpr.12550)

Citation Report

#	ARTICLE	IF	CITATIONS
1	miR-223-3p promotes autoreactive T _H 17 cell responses in experimental autoimmune uveitis (EAU) by inhibiting transcription factor FOXO3 expression. <i>FASEB Journal</i> , 2019, 33, 13951-13965.	0.2	29
2	Effect of platelet-rich plasma on implant bone defects in rabbits through the FAK/PI3K/AKT signaling pathway. <i>Open Life Sciences</i> , 2019, 14, 311-317.	0.6	3
3	Role of miR-223-3p in pulmonary arterial hypertension via targeting ITGB3 in the ECM pathway. <i>Cell Proliferation</i> , 2019, 52, e12550.	2.4	46
4	miR-223-3p promotes cell proliferation and invasion by targeting <i>Arid1a</i> in gastric cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 150-159.	0.9	30
5	CircATP2B4 promotes hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells via the miR-223/ATR axis. <i>Life Sciences</i> , 2020, 262, 118420.	2.0	13
6	Docosahexaenoic acid inhibits Ca ²⁺ influx and downregulates CaSR by upregulating microRNA-16 in pulmonary artery smooth muscle cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2020, 34, e22573.	1.4	3
7	Micro-RNA Analysis in Pulmonary Arterial Hypertension. <i>JACC Basic To Translational Science</i> , 2020, 5, 1149-1162.	1.9	24
8	DDCI-01, a novel long acting phosphodiesterase-5 inhibitor, attenuated monocrotaline-induced pulmonary hypertension in rats. <i>Pulmonary Circulation</i> , 2020, 10, 1-10.	0.8	0
9	Restoring the Platelet miR-223 by Calpain Inhibition Alleviates the Neointimal Hyperplasia in Diabetes. <i>Frontiers in Physiology</i> , 2020, 11, 742.	1.3	8
10	miR-20a-5p promotes pulmonary artery smooth muscle cell proliferation and migration by targeting ABCA1. <i>Journal of Biochemical and Molecular Toxicology</i> , 2020, 34, e22589.	1.4	11
11	MiR-193a-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4. <i>Pulmonary Circulation</i> , 2020, 10, 1-12.	0.8	3
12	Inhibition of RELM- β prevents hypoxia-induced overproliferation of human pulmonary artery smooth muscle cells by reversing PLC-mediated KCNK3 decline. <i>Life Sciences</i> , 2020, 246, 117419.	2.0	16
13	MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction. <i>Hypertension Research</i> , 2021, 44, 129-146.	1.5	24
14	Identification of aberrantly expressed circular RNAs in hyperlipidemia-induced retinal vascular dysfunction in mice. <i>Genomics</i> , 2021, 113, 593-600.	1.3	3
15	Targeting Molecular and Cellular Mechanisms of Pulmonary Arterial Hypertension. , 2021, , 407-434.		0
16	MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 610561.	1.1	26
17	Extracellular Vesicles and Their miRNA Content in Amniotic and Tracheal Fluids of Fetuses with Severe Congenital Diaphragmatic Hernia Undergoing Fetal Intervention. <i>Cells</i> , 2021, 10, 1493.	1.8	10
18	Circular RNA Expression: Its Potential Regulation and Function in Abdominal Aortic Aneurysms. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-21.	1.9	12

#	ARTICLE	IF	CITATIONS
19	miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 2187-2195.	1.4	28
20	Quercetin improves atrial fibrillation through inhibiting TGF- β 2/Smads pathway via promoting MiR-135b expression. <i>Phytomedicine</i> , 2021, 93, 153774.	2.3	24
21	STAT1 and its related molecules as potential biomarkers in <i>Mycobacterium tuberculosis</i> infection. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2866-2878.	1.6	45
22	Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease. <i>Vascular Biology (Bristol, England)</i> , 2020, 2, R17-R34.	1.2	21
23	A novel prognostic signature for idiopathic pulmonary fibrosis based on five-immune-related genes. <i>Annals of Translational Medicine</i> , 2021, 9, 1570-1570.	0.7	9
24	Transgenerational inheritance of promoter methylation changes in extrauterine growth restriction-induced pulmonary arterial pressure disorders. <i>Annals of Translational Medicine</i> , 2021, 9, 1551-1551.	0.7	0
25	MiR-223/NFAT5 signaling suppresses arterial smooth muscle cell proliferation and motility in vitro. <i>Aging</i> , 2020, 12, 26188-26198.	1.4	3
26	Integrative analysis of transcriptome-wide association study and mRNA expression profile identified candidate genes and pathways associated with aortic aneurysm and dissection. <i>Gene</i> , 2022, 808, 145993.	1.0	4
27	Non-Coding RNA Networks in Pulmonary Hypertension. <i>Frontiers in Genetics</i> , 2021, 12, 703860.	1.1	8
29	The role of TGF- β 2 or BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 288.	1.6	10
30	Effects of microRNAs in hypertension disease. <i>The European Research Journal</i> , 2022, 8, 131-138.	0.1	0
31	FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPAR γ 3. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1034-1049.	1.6	7
33	Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 443-460.	2.5	5
37	The Cellular and Molecular Effects of Fetoscopic Endoluminal Tracheal Occlusion in Congenital Diaphragmatic Hernia. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	9
38	The key roles of non-coding RNAs in the pathophysiology of hypertension. <i>European Journal of Pharmacology</i> , 2022, 931, 175220.	1.7	4
39	Targeting integrin pathways: mechanisms and advances in therapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	95
40	MiR-223-3p Aggravates Ocular Inflammation in Sjögren's Syndrome. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, 1087-1095.	0.6	2